TREVENA,INC. (NASDAQ:TRVN) Files An 8-K Entry into a Material Definitive Agreement

ME Staff 8-k
-
0

TREVENA,INC. (NASDAQ:TRVN) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.

On February28, 2018, the Board of Directors (the “Board”) of Trevena,Inc. (“Trevena” or the “Company”) the number of options awarded to a non-employee director upon initial election to the Board and annually at the Annual Meeting of Stockholders was increased by 30,000 shares and 15,000 shares, respectively. All aspects of the cash compensation of non-employee directors remained unchanged. A copy of the Trevena,Inc. Non-Employee Director Compensation Policy, effective as of Febuary 28, 2018, is attached hereto as Exhibit10.1 and incorporated herein by reference.

Item 1.01 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February28, 2018, the Board (i)approved a cash incentive award for fiscal year 2017 under the Trevena,Inc. Incentive Compensation Plan (the “ICP”) to be made to Maxine Gowen, Ph.D., the President and Chief Executive Officer (the “CEO”) of the Company, and (ii)ratified ICP cash incentive awards for fiscal year 2017 that were approved by the Compensation Committee of the Board for the Company’s executive officers other than the CEO. The individual ICP awards earned in 2017 will be paid in mid-March2018, as follows: Maxine Gowen, Ph.D., $268,785; Carrie Bourdow, $130,413; David Geoghegan, $93,554; Roberto Cuca, $111,739; Yacoub Habib, Ph.D., $107,989; John M. Limongelli, $109,169; and Jonathan Violin, Ph.D., $71,812.

Separately, the Board approved (i)for Dr.Gowen, an increase in her target cash incentive opportunity from 55% of her annual base salary to 60% of her annual base salary and (ii)for the Company’s Senior Vice Presidents, an increase in the target cash incentive opportunity from 35% of their respective annual base salary to 40% of their respective annual base salary.

Item 1.01. Financial Statements and Exhibits.

(d)Exhibits

Exhibit Number

ExhibitDescription

10.1

Trevena,Inc.Non-Employee Director Compensation Policy, effective as of February28, 2018.


TREVENA INC Exhibit
EX-10.1 2 a18-7415_1ex10d1.htm EX-10.1 Exhibit 10.1   TREVENA,…
To view the full exhibit click here

About TREVENA,INC. (NASDAQ:TRVN)

Trevena Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250. Its TRV130 is a Mu-receptor G protein Pathway Selective (Mu-GPS) modulator that activates G protein. Its TRV250 is a small molecule G protein biased ligand of the d-opioid receptor in preclinical development. Its TRV734 is a small molecule Mu-GPS that it has discovered and has developed through Phase I as a first-line, orally administered compound for the treatment of moderate to severe acute and chronic pain. Its TRV027 is a peptide b-arrestin biased ligand that targets the angiotensin II type 1 receptor (AT1R). In addition to these three product candidates, the Company has identified and has completed the Phase I program for TRV734.